AI Analyst Summary
CVS Health presents a compelling value/growth setup: a forward P/E of just 11.4x paired with a PEG of 0.26 and 188.8% YoY earnings growth signals deep undervaluation relative to the recovery trajectory across its integrated pharmacy, insurance, and health services platform. Near-unanimous analyst Buy consensus (24 of 25) and a perfect 4-of-4 recent EPS beat rate reinforce confidence in execution. The primary risk is that the earnings surge is heavily base-effect-driven, and normalization of medical costs or continued Medicaid redetermination headwinds could temper forward growth materially.
Fundamentals
Pe
Trailing P/E 25.6x / Forward P/E 11.4x · 4.0/5
Trailing P/E of 25.6x appears elevated for a healthcare plan operator, but the forward P/E compresses sharply to 11.4x — well below sector median — reflecting a meaningful earnings recovery. The forward multiple is the more relevant anchor given the earnings trajectory.
Peg
PEG 0.26 · 5.0/5
A PEG of 0.26 is exceptionally low and signals the stock is materially undervalued relative to its growth rate. This is a strong positive signal, even accounting for the base-effect contribution to the YoY earnings surge.
Analyst Rating
Strong Buy consensus (1.4) · 5.0/5
24 Buy ratings against just 3 Hold and zero Sell across 25 analysts. A consensus rating of 1.4 reflects near-unanimous bullish conviction, well above the threshold for a top-tier score.
Earnings Trend
EPS Growth +188.8% YoY · 5.0/5
YoY earnings growth of 188.8% is exceptional, likely driven by recovery from a depressed prior-year base and improving operating leverage across the pharmacy, insurance, and health services segments. Revenue growth of 7.1% provides organic underpinning to the earnings surge.
Price Target Beat
4 of 4 quarters beat (last 4 quarters) · 4.0/5
CVS has beaten EPS estimates in all 4 of the most recent quarters. Only 4 data points are available, so a score of 5 is reserved; the streak is nonetheless a strong indicator of disciplined execution and conservative guidance-setting.
Management
Consistent execution with bullish analyst alignment · 4.0/5
A perfect recent EPS beat record, near-unanimous analyst Buy consensus, and a compressing forward multiple suggest management is delivering on integration milestones across its pharmacy benefits, insurance, and MinuteClinic assets. Capital allocation clarity would be needed to elevate to a 5.
● See the full picture
Get today's top-scored picks, ranked for you.
Compass screens thousands of stocks every morning and hands you a short list of high-conviction picks — scored, explained, and re-ranked to your risk profile.
Start free for 3 days →
No credit card. Then $9/month. Cancel anytime.
How Compass scores stocks
Compass pre-filters thousands of U.S. equities by fundamentals, then an AI analyst scores each finalist 1–5 across six measures — spanning valuation, growth, analyst sentiment, and management quality — into one composite score, refreshed every market morning. Browse all covered stocks →
Not financial advice.
Compass is an analytical tool, not a registered investment adviser or broker-dealer.
Scores and recommendations are generated by AI, may be inaccurate or out of date, and are
not investment, financial, legal, or tax advice. Investing involves risk, including loss of
principal. Do your own research and consult a licensed financial professional.
About Compass.